Waverunner
Senior Member
- Messages
- 1,079
I know, this sounds like a long time but it is better than nothing. There are two main drug candidates which come to mind when we think about working celiac treatments, which hopefully can be used for other diseases as well (IBD, IBS, allergies, etc.). The first is called larazotide acetate and just finished phase 2b. What I find most interesting about this drug and the company is their whole new approach. They focus on drugs which decrease or increase intestinal permeability. Decreasing permeability could be a key to reach a balance between the body and its environment. Alba Therapeutics pipeline can be seen here:
http://www.albatherapeutics.com/Portals/0/pipeline.pdf
The second treatment is called Nexvax2. "Nexvax2® has been designed for celiac disease associated HLA DQ2, present in 90% of individuals with celiac disease (ref. 6–8). Nexvax2® encompasses three peptides that account for a substantial proportion of the T-cell reaction to gluten in patients with HLA DQ2-associated celiac disease. ImmusanT’s scientists converted these peptides into a pharmaceutical agent, Nexvax2®. In laboratory studies, Nexvax2® is capable of inducing immune tolerance to gluten. ImmusanT is in clinical trials testing whether Nexvax2® induces immune tolerance to gluten and protects the intestine from the damaging effects of gluten." It just finished phase I and therefore has still a long way to go but it is also a very interesting approach.
http://www.immusant.com/technology/
What I truly hope is, that new approaches become available for patients.
http://www.albatherapeutics.com/Portals/0/pipeline.pdf
The second treatment is called Nexvax2. "Nexvax2® has been designed for celiac disease associated HLA DQ2, present in 90% of individuals with celiac disease (ref. 6–8). Nexvax2® encompasses three peptides that account for a substantial proportion of the T-cell reaction to gluten in patients with HLA DQ2-associated celiac disease. ImmusanT’s scientists converted these peptides into a pharmaceutical agent, Nexvax2®. In laboratory studies, Nexvax2® is capable of inducing immune tolerance to gluten. ImmusanT is in clinical trials testing whether Nexvax2® induces immune tolerance to gluten and protects the intestine from the damaging effects of gluten." It just finished phase I and therefore has still a long way to go but it is also a very interesting approach.
http://www.immusant.com/technology/
What I truly hope is, that new approaches become available for patients.